Vertex's Povetacicept: Accelerated Approval Likely, But GFR Data Gap Looms Against Otsuka's Voyxact

Vertex Confident in Povetacicept Amidst IgAN Competition

Vertex Pharmaceuticals' CEO Reshma Kewalramani expressed confidence in the company's IgA nephropathy (IgAN) drug, povetacicept, despite a competitive landscape. The FDA is currently reviewing povetacicept for accelerated approval, with a decision anticipated by November 30. This optimism is partly fueled by positive two-year follow-up data for Otsuka Pharmaceuticals’ rival IgAN drug, Voyxact, from its Phase 3 VISIONARY trial, which demonstrated stabilization and improvement in kidney function, with a GFR slope of 0.3 mL/min/1.73 m² per year compared to a negative 4.2 mL/min/1.73 m² annually for placebo. Voyxact previously received accelerated approval in November 2025 based on a 51% placebo-adjusted reduction in proteinuria. Vertex's own Phase 3 RAINIER trial for povetacicept showed a 49.8% reduction in proteinuria at 36 weeks versus placebo.

• Otsuka Pharmaceuticals' two-year Phase 3 VISIONARY trial data for Voyxact demonstrated significant improvements in kidney function, with a GFR slope of 0.3 mL/min/1.73 m² per year compared to a 4.2 mL/min/1.73 m² annual decline in the placebo group. This marks the first time an FDA-approved IgAN therapy has shown stabilization and evidence of improvement in kidney function, supporting the predictive value of proteinuria reduction for clinical benefit and potentially paving the way for Voyxact's full approval.
• Vertex Pharmaceuticals' povetacicept achieved a 49.8% reduction in proteinuria at 36 weeks versus placebo in its Phase 3 RAINIER trial, positioning it strongly for accelerated approval. The FDA's target action date for povetacicept is November 30, with the company pursuing approval based on urinary protein data, similar to Voyxact's initial accelerated approval pathway. These results underscore povetacicept's potential to address a significant unmet need in IgAN.
• Vertex's povetacicept aims to differentiate itself in the growing IgAN market through its patient-centric attributes, specifically its autoinjector delivery system and monthly dosing schedule. This offers a potential advantage over competitors like Otsuka's Voyxact (prefilled syringe, monthly) and other approved therapies such as Novartis’ Fabhalta (oral, twice-daily) and Vera Therapeutics’ Trutakna (weekly subcutaneous injection), potentially enhancing patient convenience and adherence.

The Rapidly Evolving Treatment Landscape for IgA Nephropathy

The treatment paradigm for IgA nephropathy (IgAN) has undergone a fundamental transformation over the past five years, shifting from reliance on supportive care and non-specific immunosuppression toward targeted, disease-modifying therapies. This shift has been driven by an increasing mechanistic understanding of IgAN pathogenesis coupled with favorable changes in the regulatory approval pathway, which together have catalyzed an explosion of clinical drug development. Three novel therapies—nefecon, sparsentan, and iptacopan—have now received approval specifically for IgAN, marking a genuine sea change from the historical standard of care. Real-world prescribing patterns, captured in a 2021 survey of 174 nephrologists managing 869 patients across the USA, China, Japan, and several European countries, still reflected conservative, guideline-concordant approaches at that time: renin-angiotensin system inhibitors (76.3%) and corticosteroids (42.8%) remained the most frequently prescribed agents across all treatment lines, with RASi use increasing to 86.0% by third-line therapy. Notably, 17.5% of surveyed nephrologists felt their patients' treatment was not achieving optimal disease control, and persistent proteinuria (≥1 g/day) was observed regardless of region or treatment line—underscoring the unmet need that subsequent drug development has sought to address.

Recent trial data illustrate the breadth of mechanisms now being pursued. The selective endothelin receptor type A antagonist SC0062 was evaluated in a 2024 phase 2 randomized, placebo-controlled trial (NCT05687890) enrolling 131 patients with biopsy-proven IgAN and persistent proteinuria despite maximized ACE inhibitor/ARB therapy. Across 5 mg, 10 mg, and 20 mg once-daily doses over 24 weeks, SC0062 produced placebo-corrected reductions in UPCR of up to 51.6% at week 24 (20 mg dose), with no adverse impact on eGFR and, notably, a lower incidence of peripheral edema than placebo (3–6% vs. 15%)—addressing a key safety concern associated with this drug class. In a separate single-center trial conducted in Eastern India, addition of budesonide (18 mg daily) to optimized supportive care in 53 patients with biopsy-proven IgAN yielded significantly greater reductions in 24-hour proteinuria and better preserved eGFR at 9 months compared with supportive care alone (P < 0.001 for both endpoints), with comparable rates of treatment-emergent adverse events between arms.

Looking beyond these individual trials, the IgAN pipeline now spans multiple therapeutic classes: APRIL and BAFF inhibitors (sibeprenlimab, atacicept, povetacicept, telitacicept), complement pathway modulators (iptacopan, cemdisiran, ravulizumab), and other novel agents including felzartamab and sparsentan. Collectively, these approaches reflect diversification across complement inhibition, endothelin receptor antagonism, and B cell/plasma-cell-directed strategies. The field is moving toward precision nephrology, incorporating biomarker-guided therapy selection, individualized risk stratification, and combination regimens—supported by tools such as the International IgA Nephropathy Prediction Tool (IIgAN-PT), now endorsed within the 2021 KDIGO guidelines for standardized clinical decision-making. Taken together, published trial data from the past five years point to consistent improvements in proteinuria reduction and renal function preservation across mechanistically distinct agents, establishing an emerging framework for individualized, disease-modifying management of IgAN.

Differentiating Povetacicept in a Competitive IgAN Market

Published studies on IgA nephropathy (IgAN) demonstrate a clear trend of investigational therapies offering improved risk-benefit profiles compared to traditional standard-of-care, which primarily involves supportive measures and systemic corticosteroids. While corticosteroids show efficacy, particularly on hard renal outcomes, they are associated with significant adverse event risks, a key area where novel targeted agents are showing advantages.

• Systemic Corticosteroids: As a standard therapy for high-risk patients, systemic corticosteroids have demonstrated benefits on hard renal outcomes (HR 0.37) and significant proteinuria reduction. However, this efficacy is counterbalanced by the highest risk of adverse events among therapies studied (RR 3.28), with increased relapse rates noted after treatment withdrawal.

• B-Cell/Plasma-Cell Targeted Therapies: This class, which includes APRIL and BAFF inhibitors, has shown substantial efficacy, with a pooled analysis indicating a significant proteinuria reduction of -34.0%. Projections based on these results suggest a favorable effect on long-term outcomes (projected HR 0.38), positioning this class as a potent alternative to broad immunosuppression.

• Complement Pathway Inhibitors: These agents are distinguished by their ability to preserve renal function, with data demonstrating a superior eGFR preservation of +5.8 mL/min/1.73 m²/year. This benefit is accompanied by significant antiproteinuric effects, as shown by agents like cemdisiran, which achieved a placebo-adjusted geometric mean change in 24-hour UPCR of -37.4%.

• Endothelin Receptor Antagonists: Atrasentan, a selective endothelin type A receptor antagonist, demonstrated a geometric mean percentage change in UPCR of -38.1% at week 36, compared to -3.1% with placebo. The primary associated adverse event was manageable fluid retention (11.2% vs. 8.2% with placebo), which did not lead to cardiac failure or trial discontinuation.

• Targeted-Release Budesonide: This therapy acts on the intestinal mucosal immune system, providing proven benefits on renal function and proteinuria with minor systemic absorption. This localized mechanism results in fewer systemic adverse reactions and better overall tolerability compared with systemic glucocorticoids.

• Calcineurin Inhibitors (CNIs): While CNI therapy can increase the rate of complete remission compared to steroids alone (RR 2.51), it is associated with a significantly increased risk for adverse events (RR 2.21), including gastrointestinal symptoms, neurological symptoms, and hirsutism.